Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan downgrades Whitbread to 'neutral', slashes price target

(Sharecast News) - JPMorgan Cazenove downgraded Premier Inn owner Whitbread on Friday to 'neutral' from 'overweight' and slashed the price target to 3,000p from 4,400p as it took a look at European hotel stocks. The bank said it was reshuffling its preferences within hotels, revisiting its 'overweight' on France's Accor and downgrading Whitbread "on the back of a fragile UK consumer from lower income demographics".

"We become more selective with regards to our preferences, given sustained discrepancy between segments and geographies, further focusing on equity stories combining a solid RevPAR momentum and near-term positive catalysts," JPM said.

It made Accor its "top pick" and sole 'overweight', with more than 20% upside potential, as it said it benefits from the best set-up in terms of above peers average trading momentum and re-rating potential.

As far as Whitbread is concerned, JPM said that while the shares have been weak for over a year now, down around 20%, the UK consumer seems to have deteriorated lately following the UK budget, with particular weakness in retailers weighted into spending from lower income demographics.

It noted that Greggs, B&M European Value Retail and Dunelm all disappointed the market in recent statements, as well as Poundland and Primark UK.

At 0925 GMT, Whitbread shares were down 1.2% at 2,501p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.